Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Equities

002603

CNE1000015S0

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-06-13 pm EDT 5-day change 1st Jan Change
17.02 CNY -1.28% Intraday chart for Shijiazhuang Yiling Pharmaceutical Co., Ltd. -4.33% -26.22%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend Per 10 Shares for 2023 CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Yiling Pharmaceutical Gets Nod for China Clinical Trial of Tracheobronchitis Drug MT
Yiling Pharmaceutical's Lianhua Qingke Tablets Gets Nod to Become Over-the-Counter Drug; Shares Up 4% MT
Yiling Pharmaceutical Gets Nod to Trial Huoxia Cold Granules MT
Yiling Pharmaceutical Presents Clinical Data on Cardiovascular Drug at Beijing Conference MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Yiling Pharmaceutical Gets Green Light to Trial Acute Myeloid Leukemia Drug MT
Yiling Pharmaceutical Gets Greenlight to Trial G201-Na Capsules MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Announces Implementation of Cash Dividend for 2022, Payable on 17 July 2023 CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022 CI
Yiling Pharma's Hypertension Drug Passes Regulatory Evaluation in China MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022 CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Yiling Pharma Wins Nod to Trial Prostate Cancer Drug MT
Yiling Pharma Unit Gets Marketing Rights of Rujietai Capsules MT
Shijiazhuang Yiling Pharma Appoints Founder as Honorary Chairman MT
Yiling Pharma Gets Regulatory Nod for Traditional Chinese Medicine MT
Yiling Pharma’s Antibiotic Passes Consistency Test MT
Shijiazhuang Yiling’s Depression Drug Included in China’s Medical Insurance Catalog MT
Yiling Pharma’s Traditional Chinese Medicine Added to Government's Recommended Drugs For COVID-19 MT
Gloom and boom: Fund managers' top picks for 2023 RE
Chinese Shares End Year With Modest Gains; Two Shenzhen Debutants Post Mixed Results MT
Chart Shijiazhuang Yiling Pharmaceutical Co., Ltd.
More charts
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company mainly provides cardiovascular and cerebrovascular drugs and anti-cold drugs. The Company also provides food and beverage products. The Company distributes its products within domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
17.02 CNY
Average target price
20.93 CNY
Spread / Average Target
+22.99%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002603 Stock
  4. News Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  5. Yiling Pharmaceutical's Lianhua Qingke Tablets Gets Nod to Become Over-the-Counter Drug; Shares Up 4%